G 238

Drug Profile

G 238

Alternative Names: G-238

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SALVAT
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ear disorders; Mycoses

Most Recent Events

  • 22 Mar 2016 No recent reports on development identified - Phase-III for Otomycosis in Spain (Otic)
  • 01 Nov 2014 Salvat completes a phase III trial in Mycoses (Otomycosis) in Spain (Otic, drops) (NCT01993823)
  • 31 May 2013 Phase-III clinical trials in Ear disorders (otomycosis) in Spain (Otic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top